What is the treatment for thrombocytopenia (low platelet count)?

Treatment for Low Platelets (Thrombocytopenia)

When to Treat vs. Observe

Most patients with platelet counts >50,000/μL do not require treatment unless they have active bleeding, require invasive procedures, or have specific risk factors for bleeding. 1, 2

Observation Alone (No Treatment)

• Children and adults with platelet counts >30,000/μL who have no bleeding or only mild bleeding (bruising, petechiae) should be managed with observation alone 3, 1
• Patients with counts between 30-50 × 10⁹/L should avoid unnecessary glucocorticoids, IVIg, or anti-Rh(D) as routine initial treatment 1
• Bleeding risk is minimal above 50 × 10⁹/L in most clinical scenarios 2, 4

Treatment Indications

• Platelet count <20,000/μL with significant mucous membrane bleeding requires treatment and possible hospitalization 3, 1
• Platelet count <10,000/μL requires treatment regardless of symptoms due to high risk of spontaneous serious bleeding 1, 5
• Active hemorrhage at any platelet count 2
• Need for invasive procedures when platelets <50,000/μL 2

---

First-Line Treatment for Immune Thrombocytopenia (ITP)

Adults with Newly Diagnosed ITP

Corticosteroids are the standard first-line treatment for adult ITP, with prednisone 0.5-2 mg/kg/day until platelet count increases to 30-50 × 10⁹/L. 3, 1

• Prednisone should be rapidly tapered and stopped in responders after achieving target platelet count, and especially in non-responders after 4 weeks to avoid corticosteroid-related complications 3
• High-dose dexamethasone 40 mg/day for 4 days shows promising results with 50% sustained response rates and may be preferred over traditional prednisone 3
• Four cycles of dexamethasone (40 mg/day for 4 days every 14 days) produced 86% response rate with 74% having responses lasting median 8 months 3

Pediatric ITP (Age ≥1 Year)

For children requiring treatment, use either a single dose of IVIg (0.8-1 g/kg) or a short course of corticosteroids as first-line therapy. 3, 1

• IVIg should be used if a more rapid increase in platelet count is desired 3
• Single dose of anti-D can be used as first-line in Rh-positive, non-splenectomized children 3
• Anti-D therapy is contraindicated in children with decreased hemoglobin due to bleeding or evidence of autoimmune hemolysis 3

---

Emergency Management of Severe Bleeding

For life-threatening bleeding with severe thrombocytopenia, immediately hospitalize and provide high-dose parenteral glucocorticoids, IVIg, and platelet transfusions simultaneously. 1

• Platelet transfusion is indicated for active hemorrhage regardless of platelet count 2
• Combine conventional critical care measures with specific ITP treatment 1
• This represents the only scenario where platelet transfusion is appropriate in ITP 2

---

Second-Line Treatments for Refractory ITP

For Adults and Children Who Fail First-Line Therapy

Thrombopoietin receptor agonists (TPO-RAs) are now preferred second-line agents before considering splenectomy. 6

• Romiplostim (Nplate): Starting dose 1 mcg/kg subcutaneously weekly, adjusted by 1 mcg/kg increments to achieve platelet count ≥50 × 10⁹/L (maximum 10 mcg/kg) 7
• Median effective dose in adults is 2-3 mcg/kg weekly 7
• Requires weekly platelet monitoring during dose adjustment, then monthly once stable 7

Alternative Second-Line Options

• Rituximab may be considered for children/adolescents with significant ongoing bleeding despite first-line treatments or as alternative to splenectomy 3
• High-dose dexamethasone may be considered as alternative to splenectomy in chronic ITP 3
• Fostamatinib (BTK inhibitor) is another option for refractory cases 6

Splenectomy

• Reserve splenectomy for patients with chronic or persistent ITP (>12 months) who have significant bleeding, lack of response to other therapies, or quality of life considerations 3
• Initial response rate is 85%, but up to 30% of responders relapse within 10 years 1
• Should be delayed at least 12 months unless severe disease unresponsive to other measures 3

---

Special Situations

Drug-Induced Thrombocytopenia

• Immediately discontinue the offending agent 2, 8
• Most cases resolve within days to weeks after drug discontinuation 8
• Supportive care with platelet transfusion only if active bleeding 8

Heparin-Induced Thrombocytopenia (HIT)

• Stop all heparin immediately and initiate alternative anticoagulation with a non-heparin agent 2, 8
• This is a prothrombotic condition despite low platelets; bleeding is rare 2
• High mortality risk due to thromboembolic complications 8

Chronic Liver Disease

• TPO receptor agonists (avatrombopag and lusutrombopag) are FDA-approved for thrombocytopenia in chronic liver disease patients scheduled for procedures 1
• Prophylactic platelet transfusions lack evidence of benefit and carry transfusion-related risks 2

Anticoagulation Management

• Full therapeutic anticoagulation can be given with platelet count ≥50 × 10⁹/L 1
• For counts 25-50 × 10⁹/L, reduce LMWH to 50% therapeutic dose or use prophylactic dosing 1
• Consider temporarily discontinuing anticoagulation when platelet count <25 × 10⁹/L 1

---

Critical Monitoring Requirements

During Active Treatment

• Weekly complete blood counts with platelet counts during dose adjustment phase 1, 7
• Monthly CBCs once stable dose established 1, 7
• Weekly platelet monitoring for at least 2 weeks following treatment discontinuation 1, 7

Common Pitfalls to Avoid

• Do not attempt to normalize platelet counts—target is ≥50 × 10⁹/L to reduce bleeding risk 3, 7
• Bone marrow examination is unnecessary in typical ITP cases (children and adults with isolated thrombocytopenia) 3, 5
• Platelet antibody testing is not recommended due to poor sensitivity and specificity 5
• Avoid corticosteroids beyond 4 weeks in non-responders due to toxicity without benefit 3
• TPO-RAs are contraindicated in myelodysplastic syndrome (MDS) due to risk of progression to acute leukemia 7